Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA
According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
New deal strengthens Congenica’s presence in India
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
